NPS Pharmaceuticals (NPSP) 45.97 $NPSP Shire to buy

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
NPS Pharmaceuticals (NPSP) 45.97 $NPSP

Shire to buy Baxalta for around $32 billion
M2 - Tue Jan 12, 6:03AM CST
"The target Baxalta and the orphan disease market are very compelling. The market is very attractive; worth $100+ Billion and has a CAGR of12 percent, almost twice of the general drugs market. Of the top 10 projected best-selling drugs world-wide in 2015, almost seven bear the orphan status. Additionally, the market has had favorable regulatory environment, having witnessed a record year for FDA/EU/Japan orphan designations in 2014."
NPSP: 45.97 (+0.01)

Progenics Pharmaceuticals Announces the Appointment of Patrick Fabbio as Chief Financial Officer
GlobeNewswire - Mon Nov 16, 6:30AM CST
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) today announced appointment of Patrick Fabbio as Chief Financial Officer. Mr. Fabbio, the former Vice President, Global Corporate Finance at NPS Pharmaceuticals, Inc., has over 20 years of financial experience in the healthcare sector at both publicly-traded and privately-held companies.
PGNX: 4.78 (+0.12), NPSP: 45.97 (+0.01)

Global Biosimilars Market Report, 2015-2025 - The biosimilar market is projected to be worth USD 32 billion worldwide by 2025
PR Newswire Europe - Tue Nov 03, 11:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv3cc/global [http://www.researchandmarkets.com/research/hcv3cc/global]) has announced the addition of the "Global Biosimilars Market, 2015 - 2025" [http://www.researchandmarkets.com/research/hcv3cc/global] report to their offering.
BIIB: 238.62 (+4.02), UTHR: 105.28 (+1.92), CTIC: 0.40 (+0.01), CHRS: 16.47 (+0.45), JNJ: 117.38 (+0.92), NPSP: 45.97 (+0.01), IBIO: 0.63 (-0.01), EBS: 30.65 (-0.68), SLXP: 172.96 (+0.15), AMGN: 152.27 (+2.46), SPPI: 6.81 (+0.01), LLY: 73.94 (+0.87), GSK: 42.56 (+0.80), ANIK: 51.10 (+0.83), NVO: 53.40 (+0.98), BAX: 45.96 (+1.02), MRK: 57.68 (+0.64), NVS: 80.67 (+0.96)

Shire offers to buy Baxter drug spinoff for $30 billion
AP - Tue Aug 04, 3:29PM CDT
NEW YORK (AP) — The Irish drugmaker Shire is offering to buy Baxalta for about $30 billion in stock as it attempts to solidify its strengthening position in rare disease treatments.
BAX: 45.96 (+1.02), SHPG: 180.29 (+4.91), NPSP: 45.97 (+0.01), BXLT: 46.02 (-0.18)

Uptrend Call Working As NPS Pharmaceuticals Stock Rises 63.6% (NPSP)
Comtex SmarTrend(R) - Mon Apr 20, 11:12AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)

63.6% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Mon Apr 13, 10:06AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)

NPS Pharmaceuticals Shares Up 63.6% Since SmarTrend's Buy Recommendation (NPSP)
Comtex SmarTrend(R) - Mon Apr 06, 9:18AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 6 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)

Shares of NPSP Up 63.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 26, 4:47PM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)

NPS Pharmaceuticals Has Returned 63.6% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Thu Mar 19, 11:16AM CDT
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 5 months, NPS Pharmaceuticals has returned 63.62% as of today's recent price of $45.97.
NPSP: 45.97 (+0.01)

Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
BusinessWire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 0.70 (-0.03), NPSP: 45.97 (+0.01), BMY: 72.64 (+0.33), CTH.TO: 21.50 (+0.25)

Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 16, 12:00PM CST
NPS Pharmaceuticals (NPSP), which is expected to report fourth-quarter 2014 results on Feb 17, had posted a negative earnings surprise of 300% in the last quarter.
ACT: 298.98 (-2.94), SHPG: 180.29 (+4.91), NPSP: 45.97 (+0.01), ARIA: 7.54 (+0.27)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Therapy Rules Change: Gameday Ups the Ante

Updated Category News Views 110

Gameday Men's Health: Leading the Safe Peptide Charge Finally, we got some regulatory sanity stepping up to the plate with peptides. You see, the FDA's new interim policy is letting state-licensed compounding pharmacies work their magic with peptides, but only under strict medical watch. And Gameday Men's Health sure ain't wasting any time setting up shop in this fresh...

Continue Reading
Fidelis Care Opens $120K Workforce Grants for Aid

Updated Category News Views 112

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Continue Reading
Chip Earnings Fuel Market Gains Amid Volatility Dip

Updated Category News Views 56

Tech Earnings Drive Market Resilience Amid a climate of economic uncertainty, it's refreshing to see semiconductor and tech earnings offering a little backbone to the market. This week, the S&P 500 climbed 1.51%, while the Nasdaq Composite jumped 1.98% over three sessions. It's like watching Rocky get up off the mat—those indices pushing higher when it seemed like they...

Continue Reading
Read/Write Labs Tackles Brain-Tech Fusion Ambitions

Updated Category News Views 88

Buck up, investors! There's a new player on the field marrying AI and neuroscience with some serious firepower and a respectable roster. Read/Write Labs—what you might've known yesterday as Dandelion Science—has kicked off under a fresh banner, amping up efforts to decode and recode our noggin's electrical orchestra. And with the likes of Jim DiCarlo, Dan Yamins, and...

Continue Reading
Fannie Mae Q3 2026 Earnings Surpass Expectations

Updated Category News Views 84

An Upward Trend in Fannie Mae's Financials Hold onto your hats—Fannie Mae's swinging into action with hefty third-quarter numbers that'd make most firms drool. The latest figures, disclosed in their 10-Q filing, boast a net income of $4.2 billion for Q3 2026. You heard me right, billion! Now, to a market vet, these aren't digits to scoff at. And as the economy keeps...

Continue Reading
Aktia Bank: Steady Ratings, Focused Expansion in Europe

Updated Category News Views 123

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

Continue Reading
ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

Updated Category News Views 38

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Continue Reading
VeriSilicon's GLTiny: Game-Changer for Wearable Tech

Updated Category News Views 45

Revolutionizing Wearable Graphics with GLTiny There's a fresh breeze blowing through the world of wearable tech, and VeriSilicon's GLTiny seems to be at the heart of it. When the silicon giant out of Shanghai tossed GLTiny into the mix, it wasn't just throwing another chip on the barbie. Oh no, this is a real pivot towards juicing up those smart gadgets strapped to your...

Continue Reading
Ballard’s HPU Agile-H Poised to Transform Portable Energy

Updated Category News Views 76

Another Step Forward with Hydrogen Ballard's got another ace up its sleeve with the HPU Agile-H. Now here’s the kicker—everyone’s scrambling for cleaner, more portable energy solutions, and Ballard’s stepped up. Born from their acquisition of GeoPura, this lightweight hydrogen powerhouse is engineered for those spots rudely ignored by the grid. Place your bets on...

Continue Reading
Replay Sports Cards Nets STAR Award for Innovation

Updated Category News Views 82

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...

Continue Reading

Top 5 Most Recently Viewed Articles

Sollis Health Welcomes Katy Marshall as Chief Growth Officer

Updated Category News Views 511

Sollis Health Welcomes Katy Marshall as Chief Growth Officer The leading concierge medical provider has appointed Katy Marshall as Chief Growth Officer. With her extensive background in driving growth for consumer and healthcare brands, she will guide the company's marketing, sales, and product strategies. Experienced Leadership Katy brings a wealth of experience to...

Continue Reading
Kulicke & Soffa Delivers Strong Q4 Performance Highlights

Updated Category News Views 153

Strong Financial Performance in Q4 Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) reported impressive financial results for the fourth quarter, showcasing resilience and growth in a challenging market. The company achieved a net revenue of $177.6 million, reflecting its ongoing commitment to innovation and operational efficiency. Lester Wong, the Interim Chief...

Continue Reading
Unlocking Dividend Income: Strategies for Salesforce Investors

Updated Category News Views 85

Understanding Salesforce's Dividend Potential Salesforce, Inc. (NYSE: CRM) is a leading company known for its innovative cloud-based solutions. With its upcoming fourth-quarter financial results, many investors are curious about how to maximize their returns, particularly through dividends. This approach can be an excellent way to create a significant income stream while...

Continue Reading
Investigation Launched into Sage Therapeutics' Recent Drug Trials

Updated Category News Views 93

Introducing Sage Therapeutics Sage Therapeutics, Inc. (NASDAQ: SAGE) is a biopharmaceutical company dedicated to developing innovative therapies aimed at enhancing brain health. However, recent events have raised serious concerns among investors, prompting an investigation into possible violations of federal securities laws. Stock Price Affected by Recent Events FDA...

Continue Reading
Genius Group Investors Can Pursue Class Action for Losses

Updated Category News Views 208

Genius Group Limited Faces Class Action Lawsuit Genius Group Limited, recognized by its ticker symbol GNUS, is currently embroiled in a class action lawsuit aimed at addressing significant investor losses. This legal action comes as a response to alleged stock market misconduct by certain trading firms. Investors Encouraged to Take Action The law firm Bronstein, Gewirtz &...

Continue Reading